Lilly Hires PGx Consultancy Cabernet to Help Guide Drug Development | GenomeWeb
NEW YORK (GenomeWeb News) - Eli Lilly has hired the pharmacogenetics consultancy firm Cabernet Pharmaceuticals to help it make PGx-guided drug development decisions.
 
“Under the agreement, Cabernet consultants will join clinical development teams at Lilly to assist in applying pharmacogenetics to selected development projects,” Cabernet and Lilly said in a statement.
 
However, both Cabernet and Lilly are keeping a tight lid on which specific drug programs they are applying PGx strategies.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.